Effect of a symbiotic on mild cognitive impairment in older adults
Effect of the Administration of a Symbiotic (E. Faecium and Agave Inulin) on Mild Cognitive Impairment in Older Adults
This study is testing if a special mix of probiotics and fiber can help older adults with mild cognitive impairment think better over time.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 48 (estimated) |
| Ages | 70 Years to 85 Years |
| Sex | All |
| Sponsor | Anahuac University Academic / other |
| Locations | 1 site (Mexico City) |
| Trial ID | NCT05688618 on ClinicalTrials.gov |
What this trial studies
This study evaluates the impact of a symbiotic combination of Enterococcus faecium and agave inulin on cognitive function in older adults experiencing mild cognitive impairment. The research is based on the gut-microbiota-brain axis, which suggests that a balanced gut microbiota can reduce inflammation in the brain and potentially improve cognitive abilities. Participants will be administered either the symbiotic or a placebo to assess changes in cognitive performance over time. The study aims to provide insights into non-pharmacological interventions for cognitive decline in the aging population.
Who should consider this trial
Good fit: Ideal candidates are older adults diagnosed with mild cognitive impairment who can provide informed consent.
Not a fit: Patients with advanced cognitive impairment, such as Alzheimer's disease, or those with significant comorbidities affecting cognitive function may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a novel dietary approach to improve cognitive function and slow the progression of cognitive impairment in older adults.
How similar studies have performed: Previous studies have shown positive results in animal models regarding the effects of symbiotics on cognition, but this approach in humans is still being explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with mild cognitive impairment * Patients who sign the informed consent Exclusion Criteria: * Patients who do not have mild cognitive impairment * Patients with advanced cognitive impairment such as Alzheimers disease * Patients with comorbidities that influence the cognitive functions such as diabetes mellitus, cerebral ischemia or previous brain trauma * Patients who do not sign the informed consent
Where this trial is running
Mexico City
- Hospital ABC Santa Fe — Mexico City, Mexico (Recruiting)
Study contacts
- Study coordinator: Jose Juan Antonio Ibarra Arias, Medico Cirujano
- Email: jose.ibarra@anahuac.mx
- Phone: 5554197603
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.